Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.

Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation

Open access

Abstract

Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease (AD). Both cerebrospinal fluid (CSF) levels of soluble TREM2 (sTREM2), a biomarker of microglia activation, and microglia PET are increased in AD; however, whether an increase in these biomarkers is associated with reduced amyloid‐beta (Aβ) accumulation remains unclear. To address this question, we pursued a two‐pronged translational approach. Firstly, in non‐demented and demented individuals, we tested CSF sTREM2 at baseline to predict (i) amyloid PET changes over ∼2 years and (ii) tau PET cross‐sectionally assessed in a subset of patients. We found higher CSF sTREM2 associated with attenuated amyloid PET increase and lower tau PET. Secondly, in the App NL‐G-F mouse model of amyloidosis, we studied baseline 18 F‐GE180 microglia PET and longitudinal amyloid PET to test the microglia vs. Aβ association, without any confounding co‐pathologies often present in AD patients. Higher microglia PET at age 5 months was associated with a slower amyloid PET increase between ages 5‐to‐10 months. In conclusion, higher microglia activation as determined by CSF sTREM2 or microglia PET shows protective effects on subsequent amyloid accumulation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202012308

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Association between baseline amyloid and amyloid PET change A, BRegression plot showing the association between baseline AV45 PET (x‐axis) and annual AV45 PET change (y‐axis) across the entire sample (N = 300). The vertical dashed line represents the Aβ‐positivity threshold of AV45 PET SUVR > 0.079 (A). Regression plot for the association between baseline AV45 PET and annual AV45 PET change stratified by baseline CSF sTREM2 levels (B). Source data are available online for this figure.
Figure 1 Association between baseline amyloid and amyloid PET change A, BRegression plot showing the association between baseline AV45 PET (x‐axis) and annual AV45 PET change (y‐axis) across the entire sample (N = 300). The vertical dashed line represents the Aβ‐positivity threshold of AV45 PET SUVR > 0.079 (A). Regression plot for the association between baseline AV45 PET and annual AV45 PET change stratified by baseline CSF sTREM2 levels (B). Source data are available online for this figure.CC BY · PubMed Central
Figure EV1 Sliding window analysis of sTREM2 effects on AV45 change rates Sliding window analysis (n = 100 per window, shifted in steps of 10) of sTREM2 effects on AV45 change rates at different levels of baseline AV45. For each window, subjects were divided into high vs. low sTREM2 via median split, and standardized group differences in AV45 change were determined as Cohen's d. The vertical dashed line marks the level of baseline AV45 at which subsequent AV45 changes are highest.Source data are available online for this figure.
Figure EV1 Sliding window analysis of sTREM2 effects on AV45 change rates Sliding window analysis (n = 100 per window, shifted in steps of 10) of sTREM2 effects on AV45 change rates at different levels of baseline AV45. For each window, subjects were divided into high vs. low sTREM2 via median split, and standardized group differences in AV45 change were determined as Cohen's d. The vertical dashed line marks the level of baseline AV45 at which subsequent AV45 changes are highest.Source data are available online for this figure.CC BY · PubMed Central
Figure 2 Rate of change in Florbetaben PET vs. baseline GE180 PET A, BBoxplots (central band = median, boxes = quartiles, whiskers = 1.5 * interquartile range), illustrating the differences in GE180 PET (A) and the rate of change in Florbetaben PET (B) compared between wild‐type C57BL/6 mice (n = 43) and APPNL‐G-G (n = 15).CThe regression plot shows lower rate of change in Florbetaben PET to be associated with lower GE180 PET at baseline, i.e., at 5 months of age (C). The shaded area corresponds to the 95% CI of the regression line. Source data are available online for this figure.
Figure 2 Rate of change in Florbetaben PET vs. baseline GE180 PET A, BBoxplots (central band = median, boxes = quartiles, whiskers = 1.5 * interquartile range), illustrating the differences in GE180 PET (A) and the rate of change in Florbetaben PET (B) compared between wild‐type C57BL/6 mice (n = 43) and APPNL‐G-G (n = 15).CThe regression plot shows lower rate of change in Florbetaben PET to be associated with lower GE180 PET at baseline, i.e., at 5 months of age (C). The shaded area corresponds to the 95% CI of the regression line. Source data are available online for this figure.CC BY · PubMed Central
Figure 3 Brain rendering of GE180 and Florbetaben PET by group and time point A–CCoronal (top row) and axial (bottom row) slices of average 18‐F GE-180 TSPO (microglia) tracer and 18F‐florbetaben amyloid PET split up by group (A–C): C57BL/6 (A), APPNL‐G-F mice subgroup with a low (< median) GE‐180 PET (B), and the APPNL‐G-F mice subgroup with a high (> median) GE‐180 PET (C). APPNL‐G-F mice with low baseline GE180 PET levels showed faster increase in Florbetaben PET between 5 and 10 months (B) compared to those at high baseline level of GE‐180 PET (C).
Figure 3 Brain rendering of GE180 and Florbetaben PET by group and time point A–CCoronal (top row) and axial (bottom row) slices of average 18‐F GE-180 TSPO (microglia) tracer and 18F‐florbetaben amyloid PET split up by group (A–C): C57BL/6 (A), APPNL‐G-F mice subgroup with a low (< median) GE‐180 PET (B), and the APPNL‐G-F mice subgroup with a high (> median) GE‐180 PET (C). APPNL‐G-F mice with low baseline GE180 PET levels showed faster increase in Florbetaben PET between 5 and 10 months (B) compared to those at high baseline level of GE‐180 PET (C).CC BY · PubMed Central
Figure 4 TREM2 vs. tau PET Effects of sTREM2 on AV1451‐PET‐assessed tau pathology stratified by Braak stages shown as boxplots (central band = median, boxes = quartiles, whiskers = 1.5 * interquartile range).Source data are available online for this figure.
Figure 4 TREM2 vs. tau PET Effects of sTREM2 on AV1451‐PET‐assessed tau pathology stratified by Braak stages shown as boxplots (central band = median, boxes = quartiles, whiskers = 1.5 * interquartile range).Source data are available online for this figure.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 94 references

Cited by

See all 134

Metadata

Authors
Ewers, M., Biechele, G., Suárez‐Calvet, M., Sacher, C., Blume, T., Morenas‐Rodriguez, E., Deming, Y., Piccio, L., Cruchaga, C., Kleinberger, G., Shaw, L., Trojanowski, J. Q., Herms, J., Dichgans, M., (ADNI), T. A. D. N. I., Brendel, M., Haass, C., & Franzmeier, N.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • Ludwig-Maximilians-Universität München (DE)
  • Pasqual Maragall Foundation (ES)
  • University of Wisconsin–Madison (US)
  • The University of Sydney (AU)
  • Washington University in St. Louis (US)
  • University of Pennsylvania (US)
  • Institut für Schlaganfall- und Demenzforschung (DE)
Corresponding author
Ewers, Michael
Venue
EMBO Molecular Medicine
Published
2020-08-10
Volume
12
Issue
9
Pages
e12308-e12308
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W3047911986
Cited by
133
References
94
Citations by year
2026: 15 · 2025: 27 · 2024: 27 · 2023: 19 · 2022: 20 · 2021: 20 · 2020: 5
FWCI
9.59
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (acceptedVersion, cc-by)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
  • DZNE Pub (submittedVersion, cc-by)
Funders
  • LMUexcellent
  • Deutsche Forschungsgemeinschaft (EXC 1010 SyNergy, HA1737/16-1)
  • HHS | National Institutes of Health (U01 AG024904)
  • U.S. Department of Defense (W81XWH-12-2-0012)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
soluble TREM2, cerebrospinal fluid biomarkers, microglial activation, amyloid-beta deposition, Alzheimer's disease, amyloid PET, tau PET, neuroinflammation, amyloid plaques
MeSH terms
Alzheimer Disease, Animals, Humans, Membrane Glycoproteins, Receptors, Immunologic, Biomarkers, Amyloid beta-Peptides, tau Proteins, Microglia, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. https://app.cochat.ai/papers/10.15252/emmm.202012308
The paper
Ewers, M., Biechele, G., Suárez‐Calvet, M., Sacher, C., Blume, T., Morenas‐Rodriguez, E., Deming, Y., Piccio, L., Cruchaga, C., Kleinberger, G., Shaw, L., Trojanowski, J. Q., Herms, J., Dichgans, M., (ADNI), T. A. D. N. I., Brendel, M., Haass, C., & Franzmeier, N. (2020). Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202012308

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.